Stifel Nicolaus Downgrades Evofem Biosciences (NASDAQ:EVFM) to Hold
Stifel Nicolaus Downgrades Evofem Biosciences (NASDAQ:EVFM) to Hold
Evofem Biosciences (NASDAQ:EVFM – Get Rating) was downgraded by Stifel Nicolaus from a "buy" rating to a "hold" rating in a research note issued to investors on Wednesday, The Fly reports.
艾芬生物科學 (納斯達克:EVFM — 獲得評分) 在週三發給投資者的研究報告中，斯蒂菲爾·尼古拉斯（Stifel Nicolaus）將評級從「買入」評級降級為「持有」評級，《蒼蠅》報告。
Separately, HC Wainwright raised their price target on shares of Evofem Biosciences to $4.00 and gave the stock a "buy" rating in a research note on Monday, August 15th.
另外，HC 溫賴特提高了對 Evofem 生物科學股份的價格目標 $4.00 並在 8 月 15 日星期一的研究報告中給了股票「買入」評級。
Evofem Biosciences Stock Down 5.2 %
艾芬生物科學股票下降 5.2%
Shares of EVFM opened at $0.09 on Wednesday. The stock has a market capitalization of $9.57 million, a P/E ratio of 0.00 and a beta of -0.93. Evofem Biosciences has a twelve month low of $0.08 and a twelve month high of $11.20. The company has a 50 day moving average of $0.32 and a 200-day moving average of $1.30.
EVFM 的股份於星期三開市 0.09 美元。該股的市值為 957 萬美元，市盈率為 0.00，貝塔值為 -0.93。伊弗姆生物科學有十二個月低點 0.08 美元和十二個月的高點 11.20 美元。該公司擁有 50 天移動平均線為 0.32 美元，200 天移動平均線為 1.30 美元。
Institutional Investors Weigh In On Evofem Biosciences
機構投資者權衡 Evofem 生物科學
A hedge fund recently raised its stake in Evofem Biosciences stock. State Street Corp increased its stake in Evofem Biosciences, Inc. (NASDAQ:EVFM – Get Rating) by 4.5% in the 1st quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 393,070 shares of the biotechnology company's stock after buying an additional 17,021 shares during the quarter. State Street Corp owned approximately 3.23% of Evofem Biosciences worth $134,000 as of its most recent SEC filing. Institutional investors and hedge funds own 13.49% of the company's stock.
一家對沖基金最近募集了 Evofem 生物科學股份的股份。根據該公司在最近的 13F 向證券交易委員會提交的文件中稱，州街公司在 Evofem 生物科學公司（NASDAQ：EVFM-獲得評級）的股份在第一季度增加了 4.5％。該基金在本季度額外購買 17,021 股股票後，擁有該生物科技公司股票的 393,070 股股份。國家街公司擁有約 3.23％ 的 Evofem 生物科學價值 $134,000 作為其最新的 SEC 文件。機構投資者和對沖基金擁有公司股票的 13.49％。
About Evofem Biosciences
關於伊芙姆生物科學
(Get Rating)
(取得評分)
Evofem Biosciences, Inc, a biopharmaceutical company, develops and commercializes various products to address unmet needs in women's sexual and reproductive health. Its commercial product is Phexxi, a vaginal gel for the prevention of pregnancy. The company is also involved in the development of EVO100, an antimicrobial vaginal gel for the prevention of urogenital transmission of Chlamydia trachomatis infection and Neisseria gonorrhoeae infection in women.
Evofem Biosciences, Inc 是一家生物製藥公司，致力於開發和商業化各種產品，以滿足女性性和生殖健康方面未滿足的需求。它的商業產品是 Pexxi，一種用於預防懷孕的陰道凝膠。該公司還參與研發 EVO100，這是一種抗菌陰道凝膠，用於預防女性沙眼衣原體感染和淋病奈瑟氏菌感染的泌尿生殖系統傳播。
Featured Stories
特色故事
- Get a free copy of the StockNews.com research report on Evofem Biosciences (EVFM)
- Does the Zillow Stock Forecast Hint Toward a Turnaround?
- Will MGM Resorts Rise to the Top of the Casino Food Chain?
- Does Short Selling In AMC Mean The Stock Is A Horror Movie?
- The Rally in Walgreen's Boots Alliance May be Short Lived
- Domino's Pizza Rises To The Occasion In Q3
- 獲取有關艾沃芬生物科學（EVFM）的研究報告的免費副本
- Zillow 股票預測是否暗示轉彎？
- 米高梅度假村會升到賭場食物鏈的頂端嗎？
- AMC 中的賣空是否意味著股票是恐怖電影？
- 沃爾格林靴子聯盟的集會可能是短暫的
- 多米諾骨牌的比薩在第三季度升起
Receive News & Ratings for Evofem Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Evofem Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.
接收 Evofem 生物科學日報的新聞和評分 -在下面輸入您的電子郵件地址，以通過 MarketBeat.com 的免費每日電子郵件通訊接收 Evofem 生物科學及相關公司的最新新聞和分析師評級的簡要每日摘要。
譯文內容由第三人軟體翻譯。